Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancer

about

Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway.Quantitative determination of erlotinib in human serum using competitive enzyme-linked immunosorbent assay.

P2860

Q50067502-3BFD5D76-B7DC-4EE7-A7B9-5EB752F0060C Q54111719-CB8C1F9A-EF0F-45AD-A0CA-6098D1C706D9

P2860

Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancer

Item

http://www.wikidata.org/entity/Q36524171

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Prolonged complete response fo ...... in advanced pancreatic cancer

@ast

Prolonged complete response fo ...... in advanced pancreatic cancer

@en

type

Item

label

Prolonged complete response fo ...... in advanced pancreatic cancer

@ast

Prolonged complete response fo ...... in advanced pancreatic cancer

@en

prefLabel

Prolonged complete response fo ...... in advanced pancreatic cancer

@ast

Prolonged complete response fo ...... in advanced pancreatic cancer

@en

P1476

Prolonged complete response fo ...... in advanced pancreatic cancer

@en

P2093

Anna Nowak-Dement

http://www.w3.org/2001/XMLSchema#string

Cezary Szczylik

http://www.w3.org/2001/XMLSchema#string

Jan Korniluk

http://www.w3.org/2001/XMLSchema#string

Piotr Korzeń

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer.

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer.

Evolution of systemic therapy for advanced pancreatic cancer.

Estimates of cancer incidence and mortality in Europe in 2008.

Update on epidermal growth factor receptor mutations in non-small cell lung cancer.

Role of erlotinib in the management of pancreatic cancer.

Recent updates on the role of chemotherapy in pancreatic cancer.

Multimodality imaging of pancreatic ductal adenocarcinoma: a review of the literature.

P304

1101-1104

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2015.4009

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Anna M Czarnecka

Wojciech Kukwa

P577

2015-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

286378730

http://www.w3.org/2001/XMLSchema#string

P698

26893699

http://www.w3.org/2001/XMLSchema#string

P932

4734067

http://www.w3.org/2001/XMLSchema#string

Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancer

about

P2860

P2860

Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932